News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
762,889 Results
Type
Article (53447)
Company Profile (532)
Press Release (708898)
Multimedia
Podcasts (140)
Webinars (20)
Section
Business (212900)
Career Advice (2098)
Deals (36653)
Drug Delivery (129)
Drug Development (86398)
Employer Resources (174)
FDA (17225)
Job Trends (15490)
News (361556)
Policy (34286)
Tag
2027 BioMidwest Elite (1)
2027 Biotech Bay Standard (2)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (3)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2814)
Academic (1)
Accelerated approval (37)
Adcomms (31)
Allergies (154)
Alliances (52246)
ALS (184)
Alzheimer's disease (1817)
Antibody-drug conjugate (ADC) (348)
Approvals (17446)
Artificial intelligence (567)
Autoimmune disease (182)
Automation (44)
Bankruptcy (374)
Best Places to Work (12076)
BIOSECURE Act (21)
Biosimilars (204)
Biotechnology (365)
Bladder cancer (167)
Brain cancer (65)
Breast cancer (675)
Cancer (5112)
Cardiovascular disease (459)
Career advice (1774)
Career pathing (38)
CAR-T (305)
CDC (58)
Celiac Disease (2)
Cell therapy (815)
Cervical cancer (39)
Clinical research (73334)
Collaboration (1860)
Company closure (4)
Compensation (1217)
Complete response letters (73)
COVID-19 (2903)
CRISPR (104)
C-suite (920)
Cystic fibrosis (153)
Data (6475)
Decentralized trials (2)
Denatured (40)
Depression (151)
Diabetes (525)
Diagnostics (6990)
Digital health (50)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (284)
Drug pricing (204)
Drug shortages (29)
Duchenne muscular dystrophy (251)
Earnings (92693)
Editorial (65)
Employer branding (21)
Employer resources (153)
Events (124045)
Executive appointments (1033)
FDA (20466)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (11)
Frontotemporal dementia (24)
Funding (1573)
Gene editing (223)
Generative AI (48)
Gene therapy (670)
GLP-1 (1069)
Government (4977)
Grass and pollen (6)
Guidances (385)
Healthcare (19684)
HIV (66)
Huntington's disease (51)
IgA nephropathy (89)
Immunology and inflammation (299)
Immuno-oncology (69)
Indications (122)
Infectious disease (3210)
Inflammatory bowel disease (216)
Inflation Reduction Act (17)
Influenza (128)
Intellectual property (262)
Interviews (330)
IPO (17164)
IRA (55)
Job creations (3796)
Job search strategy (1478)
JPM (68)
Kidney cancer (17)
Labor market (86)
Layoffs (601)
Leadership (34)
Legal (8201)
Liver cancer (97)
Longevity (15)
Lung cancer (695)
Lymphoma (390)
Machine learning (43)
Management (59)
Manufacturing (840)
MASH (177)
Medical device (14187)
Medtech (14246)
Mergers & acquisitions (20581)
Metabolic disorders (1374)
Multiple sclerosis (174)
NASH (21)
Neurodegenerative disease (371)
Neuropsychiatric disorders (102)
Neuroscience (3174)
Neurotech (1)
NextGen: Class of 2026 (6971)
Non-profit (4797)
Now hiring (68)
Obesity (661)
Opinion (299)
Ovarian cancer (170)
Pain (210)
Pancreatic cancer (243)
Parkinson's disease (309)
Partnered (35)
Patents (519)
Patient recruitment (520)
Peanut (63)
People (61379)
Pharmaceutical (95)
Pharmacy benefit managers (32)
Phase 1 (22910)
Phase 2 (32194)
Phase 3 (24004)
Pipeline (5630)
Policy (318)
Postmarket research (2819)
Preclinical (9909)
Press Release (69)
Prostate cancer (253)
Psychedelics (58)
Radiopharmaceuticals (306)
Rare diseases (965)
Real estate (6203)
Recruiting (71)
Regulatory (25852)
Reports (53)
Research institute (2626)
Resumes & cover letters (360)
Rett syndrome (28)
RNA editing (21)
RSV (88)
Schizophrenia (160)
Series A (261)
Series B (203)
Service/supplier (11)
Sickle cell disease (107)
Special edition (27)
Spinal muscular atrophy (172)
Sponsored (45)
Startups (3892)
State (2)
Stomach cancer (20)
Supply chain (109)
Tariffs (87)
The Weekly (98)
Vaccines (1132)
Venture capital (100)
Weight loss (437)
Women's health (99)
Worklife (19)
Date
Today (137)
Last 7 days (712)
Last 30 days (2487)
Last 365 days (31314)
2026 (4357)
2025 (31603)
2024 (36928)
2023 (41632)
2022 (52983)
2021 (57510)
2020 (55954)
2019 (48485)
2018 (36548)
2017 (33964)
2016 (33589)
2015 (39569)
2014 (33461)
2013 (28698)
2012 (30726)
2011 (31215)
2010 (29606)
Location
Africa (831)
Alabama (91)
Alaska (7)
Arizona (324)
Arkansas (15)
Asia (42449)
Australia (7169)
California (11796)
Canada (3367)
China (1185)
Colorado (497)
Connecticut (515)
Delaware (347)
Europe (94969)
Florida (1760)
Georgia (370)
Hawaii (3)
Idaho (62)
Illinois (916)
India (72)
Indiana (539)
Iowa (24)
Japan (449)
Kansas (133)
Kentucky (45)
Louisiana (28)
Maine (72)
Maryland (1449)
Massachusetts (8598)
Michigan (332)
Minnesota (655)
Mississippi (5)
Missouri (132)
Montana (35)
Nebraska (28)
Nevada (125)
New Hampshire (84)
New Jersey (3151)
New Mexico (32)
New York (3097)
North Carolina (1603)
North Dakota (9)
Northern California (5727)
Ohio (346)
Oklahoma (21)
Oregon (47)
Pennsylvania (2348)
Puerto Rico (25)
Rhode Island (49)
South America (1179)
South Carolina (69)
South Dakota (1)
Southern California (4573)
Tennessee (179)
Texas (1812)
United States (42052)
Utah (350)
Vermont (1)
Virginia (284)
Washington D.C. (83)
Washington State (978)
West Virginia (4)
Wisconsin (119)
Wyoming (2)
762,889 Results for "rare disease therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Rare diseases
JPM Day 3: Rare Disease in the Spotlight
2026 is shaping up to be a pivotal year for rare disease drugmakers, with key approvals, filings and readouts lined up for this year.
January 15, 2026
·
5 min read
·
Tristan Manalac
Rare diseases
Rare Disease Biotechs Stand To Lose $4B if Priority Voucher Program Not Reinstated: Report
Some 200 rare disease therapies are at risk of losing eligibility for a pediatric priority review voucher, a recent analysis by the Rare Disease Company Coalition shows. That could mean $4 billion in missed revenue for already cash-strapped biotechs.
January 26, 2026
·
7 min read
·
Heather McKenzie
Insights
From Awareness to Acceleration: Rare Disease Drug Development Enters a Pivotal Era
Investor enthusiasm and evolving FDA pathways are accelerating rare disease drug development, with ultrarare conditions like MPS II moving into the spotlight.
February 4, 2026
·
3 min read
·
Jennifer Smith-Parker
Drug Development
Biopharma Momentum To Propel Rare Disease, Cancer, Neuro Forward in 2026
After years stuck in the “doldrums,” the biopharma sector is in a “very good place” heading into the new year, analysts told
BioSpace
, with both rare and chronic diseases headlining investor and R&D interest as JPM26 kicks off.
January 12, 2026
·
6 min read
·
Heather McKenzie
Rare diseases
Rare Disease Vouchers Caught in Political Abyss. It Didn’t Have To Be This Way
The FDA’s rare pediatric disease priority review voucher program missed reauthorization at the last minute in 2024; advocates have been fighting to get it back ever since.
January 23, 2026
·
3 min read
·
Heather McKenzie
Rare diseases
Rare Pediatric Disease Vouchers Reauthorized, PBM Reform Funded in Narrowly Passed Spending Bill
U.S. President Donald Trump signed a spending package into law Tuesday that reauthorizes the FDA’s previously stalled rare pediatric disease priority review voucher program, among other initiatives, while ending a three-day partial government shutdown.
February 3, 2026
·
3 min read
·
Heather McKenzie
FDA
Calls for Leadership Stability and Rare Disease Follow-Through at FDA in 2026
After a tumultuous year, experts call for stability while anticipating the first fruits of policies intended to expedite approvals for rare disease drugs.
January 5, 2026
·
9 min read
·
Tristan Manalac
Rare diseases
Despite Wide Support for Rare Disease, Voucher Program Caught Up in Senate’s ICE Fight
The Senate failed to pass a massive spending bill on Thursday—which includes the rare pediatric PRV program but also funding for the Immigration and Customs Enforcement’s large-scale crackdown in Minnesota and other states.
January 30, 2026
·
3 min read
·
Annalee Armstrong
FDA
Rare Disease Leaders Call for Regulatory Consistency After Chaotic Year
As the FDA unveils a parade of initiatives aimed at accelerating drug development for rare diseases, experts appeal for a consistent approval process that will support and further catalyze momentum.
December 8, 2025
·
8 min read
·
Heather McKenzie
Deals
Moderna Teams With Recordati on Rare Disease mRNA Therapy for up to $160M
Moderna will continue to lead clinical development and manufacturing of the asset, while Recordati will handle commercialization of mRNA-3927, which is under development for the rare metabolic disorder propionic acidemia.
January 30, 2026
·
1 min read
·
Annalee Armstrong
1 of 76,289
Next
